Effect of all-trans retinoic acid on chemotherapy induced apoptosis and down-regulation of Bcl-2 in human myeloid leukaemia CD34 positive cells

Leukemia Research

Volumn 23, Issue 8, 1999, Pages 741-749

  Ahmed, N ^a   Laverick, L ^a   Sammons, J ^a   Baumforth, K R N ^a   Hassan, H T ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; CD34; Fludarabine; Leukaemia; Retinoic acid

Indexed keywords

CD34 ANTIGEN; CD7 ANTIGEN; CYTARABINE; FLUDARABINE; GLYCOPROTEIN P; PROTEIN BCL 2; RETINOIC ACID;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032791131     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00084-3     Document Type: Article

References (59)

1. Burnett A.K., Eden O.B. Treatment of acute leukaemia. Lancet. 349:1997;270-275.
2. Hassan H.T., Zander A.R. Haematopoietic cytokines in the biology and treatment of acute myeloid leukaemia. Oncol. Rep. 4:1997;1141-1149.
3. Hassan H.T., Freund M. Stem cell factor protects CD34 positive human myeloid leukaemia cells from chemotherapy-induced apoptosis. Pieters R. Drug Resistance in Leukemia and Lymphoma. 1995;123-127 Gordon and Breach, Harwood.
4. Al-Alami O., Sammons J., Martin J.H., Hassan H.T. Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and CD34 negative human leukaemia cells. Leuk. Res. 22:1998;939-945.
5. Sonneveld P. Multidrug resistance in acute myeloid leukaemia. Balliere's. Clin. Haematol. 9:1996;185-203.
6. van den Heuvel-Eibrink M.M., van der Holt B., te Boekhorst P.A., Pieters R., Schoester M., Lowenberg B., Sonneveld P. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br. J. Haematol. 99:1997;76-83.
7. Hynault M., Zhou D., Delmer A., Ramond S., Viguie F., Cadiou M., Perrot J.Y., Levy V., Rio B., Cymbalista F., Zittoun R., Marie J.P. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann. Hematol. 74:1997;65-71.
8. Del Poeta G., Venditti A., Aronica G. et al. P-glycoprotein expression in de novo acute myeloid leukemia. Leuk. Lymph. 27:1997;257-274.
9. Miwa H., Nakase K., Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk. Lymph. 21:1996;239-244.
10. Wilman C.L. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research program. Semin. Hematol. 34:1997;25-33.
11. Venditti A., DelPoeta G., Buccisano F. et al. Prognostic relevance of the expression of TdT and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 12:1998;1056-1063.
12. Saxena A., Sheridan D.P., Card R.T., McPeek A.M., Mewdell C.C., Skinnider L.F. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am. J. Hematol. 58:1998;278-284.
13. Legrand O., Simonin G., Perrot J.Y., Zittoun R., Marie J.P. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 91:1998;4480-4488.
14. Lamy T., Drenou B., Brulois I. et al. Multidrug-resistance (MDR) activity in acute-leukemia determined by Rhodamine-123 efflux assay. Leukemia. 9:1995;1549-1555.
15. Hassan H.T., Freund M. Effect of human stem cell factor on chemotherapy-induced apoptosis in myeloid leukaemia cells. Eur. J. Cancer. 31:1995;1883-1884.
16. Douglas Smith B., Bambach B.J., Vala M.S. et al. Inhibited apoptosis and drug resistance in acute myeloid leukaemia. Br. J. Haematol. 102:1998;1042-1049.
17. Friesen C., Herr I., Krammer P.H., Debatin K.M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukaemia cells. Nat. Med. 2:1996;574-577.
18. Smyth M.J., Krasovskis E., Sutton V.R., Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumour cells from multiple forms of caspase-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 95:1998;7024-7029.
19. Reed J.C. Double identity for proteins of the Bc1-2 family. Nature. 387:1997;773-776.
20. Miyashita T., Reed J.C. Bc1-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81:1993;151-157.
21. Vario G., Innes K.M., Adams J.M. Bc1-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene. 13:1996;1511-1519.
22. Campos L., Oriol P., Sabido O., Guyotat D. Spontaneous expression of P-glycoprotein and Bc1-2 in acute myeloid leukemia blast cells. Leuk. Lymph. 27:1997;119-125.
23. Lohri A., van Hille B., Bacchi M., Fopp M., Joncourt F., Reuter J., Cerny T., Fey M.F., Herrmann R. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bc1-2 and topoisomerase lialpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK). Eur. J. Haematol. 59:1997;206-215.
24. Bradbury D.A., Aldington S., Zhu Y.M., Russell N.H. Down-regulation of bc1-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br. J. Haematol. 94:1996;671-675.
25. Pisani F., Del Poeta G., Aronica G., Venditti A., Caravita T., Amadori S. In vitro downregulation of Bc1-2 expression by all-trans retinoic acid in AML blasts. Ann. Hematol. 75:1997;145-147.
26. Freund A., Boos J., Harkin S. et al. Augmentation of 1-β-D-arabinofuranosylcytosine (AraC) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs. Eur. J. Cancer. 34:1998;895-901.
27. Ketley N.J., Allen P.D., Kelsey S.M., Newland A.C. Modulation of idarubicin-induced apoptosis in human acute myeloid leukaemia blasts by all-trans retinoic acid, 1,25(OH) 2 vitamin D3 and GM-CSF. Blood. 90:1997;4578-4587.
28. Kakihara T., Fukuda T., Kamishima T. et al. Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines. Leuk. Lymph. 26:1997;369-376.
29. Estey E.H. New agents for the treatment of acute myelogenous leukemia: focus on topotecan and retinoids. Leuk. 12 (Suppl 1):1998;S13-S15.
30. Hassan H.T., Gutensohn K., Zander A.R., Kuehnl P. CD34+ cell sorting and enrichment: applications in blood banking and transplantation. Recktenwald D., Radbruch A. Cell Separation Methods and Applications. 1998;283-292 Marcel Dekker, 1998.
31. Dalal B.I., Wu V., Barnett M.J. Induction failure in de novo AML is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk. Lymph. 26:1997;299-306.
32. Fardel O., Payen L., Courtois A. et al. Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KGla leukemic cells. Int. J. Oncol. 12:1998;315-319.
33. Bailley J.D., Muller C., Jaffrezou J.P. et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia. 9:1995;899-907.
34. Hassan H.T., Veit A., Maurer H.R. Synergistic interactions between differentiation inducing agents in inhibiting proliferation of HL-60 human myeloid leukaemia cells in clonogenic microassay. J. Cancer. Res. Clin. Oncol. 117:1991;227-231.
35. Ahmed N, Sammons J, Hassan HT. Bc1-2 protein in human myeloid leukaemia cells and its down-regulation during chemotherapy-induced apoptosis. Oncology Reports 1999;6(2):403-7.
36. Porwit-MacDonald A., Ivory K., Wilkinson S., Wheatley K., Wong L., Janossy G. Bc1-2 expression in normal human bone marrow precursors and in acute myeloid leukemia. Leukemia. 9:1995;1191-1198.
37. Lauria F., Raspadori D., Rondelli D., Ventura M.A., Fiacchini M., Visani G., Forconi F., Tura S. High bc1-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia. 11:1997;2075-2078.
38. Bradbury D.A., Zhu Y.M., Russell N.H. Bc1-2 expression in acute myeloblastic leukaemia: relationship with autonomous growth and CD34 antigen expression. Leuk. Lymph. 24:1997;221-228.
39. Campos L., Rouault J.P., Sabido O., Oriol P., Roubi N., Vasselon C., Archimbaud E., Maguad J.P., Guyotat D. High expression of bc1-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 81:1993;3091-3096.
40. Karakas T., Maurer U., Weidmann E., Miething C.C., Hoelzer D., Bergmann L. High expression of bc1-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol. 9:1998;159-165.
41. Lotem J., Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bc1-2 dependent and independent pathways. Cell. Growth. Differ. 5:1994;321-327.
42. Guedez L., Suresh A., Tung F., Zucali J. Quantitation of resistance to cytosine arabinoside by myeloid leukemic cells expressing bc1-2. Eur. J. Haematol. 57:1996;149-156.
43. Klumper E., Ossenkoppele G.J., Pieters R. et al. In vitro resistance to cytarabine, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br. J. Haematol. 93:1996;903-910.
44. Francis G.E., Guimaraes J.E.T.E., Berney J.J., Wing M.A. Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and AML. Leuk. Res. 9:1985;573-581.
45. Hassan H.T. Synergism between differentiation agents: pre-clinical and clinical studies in myeloid leukaemia. Rifkind R.A. The Pharmacology of Cell Differentiation. 1993;277-294 Elsevier, Amsterdam.
46. Venditti A., Stasi R., Del Poeta G. et al. All-trans retinoic acid and low dose cytosine arabinoside for the treatment of poor-prognosis AML. Leukemia. 9:1995;1121-1125.
47. Hu Z.B., Minden M.D., McCulloch E.A. Direct evidence for the participation of bc1-2 in the regulation of retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leuk. 9:1995;1667-1673.
48. Marks D.C., Su G.M., Davey R.A., Davey M.W. Extended multidrug resistance in haemopoietic cells. BrJ. Haematol. 95:1996;587-595.
49. Grey M., Borg A.G., Wood P., Burgess R., Fisher A., Yin J.A. Effect of cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 of cytotoxic agents in acute myeloid leukaemia. Leuk. Res. 21:1997;867-874.
50. Liu Yin JA, Wheatley K, Rees J. Burnett A. Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory AML: results of the UK MRC AML-R trial. Blood 1998;92(Suppl 1,231a):946.
51. Douer M., Koeffler H.P. Retinoic acid enhances colony stimulating factor induced clonal growth of normal human myeloid progenitor cells in vitro. Exp. Cell. Res. 138:1982;193-198.
52. Bleiberg I., Fabian I., Kantor S., Kletter Y. The effect of retinoic acid on haematopoiesis in human long term bone marrow culture. Leuk. Res. 12:1988;545-550.
53. Middelhoff G. Ball I. Retinoic acids in normal and leukaemic cell cultures: effects on monocyto- and granulocytopoiesis. Exp Hematol 1989; 17, Suppl. 665A.
54. Benito A., Grillot D., Nunez G., Fernandez-Luna J.L. Regulation and function of Bc1-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am. J. Pathol. 146:1995;481-490.
55. Benito A., Silva M., Grillot D., Nunez G., Fernandez-Luna J.L. Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-xL. Blood. 87:1996;3837-3843.
56. Kumakura S. Ishikura H. Tsumura H. Iwata Y. Endo J. Kobayashi S. c-Myc and Bc1-2 protein expression during the induction of apoptosis and differentiation in TNF alpha-treated HL-60 cells. Leuk Lymph 1996; 23: 383-394.
57. Sanz C., Benito A., Silva M., Albella B., Richard C., Segovia J.C., Insunza A., Bueren J.A., Fernandez-Luna J.L. The expression of Bcl-x is down-regulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage. Blood. 89:1997;3199-3204.
58. Bruel A., Karsenty E., Schmid M., McDonnell T.J., Lanotte M. Altered sensitivity to retinoidinduced apoptosis associated with changes in the subcellular distribution of Bc1-2. Exp. Cell Res. 233:1997;281-287.
59. Ray S., Bullock G., Nunez G., Tang C., Ibrado A.M., Huang Y., Bhalla K. Enforced expression of Bcl-xs induces differentiation and sensitises CML-blast crisis K562 cells to 1-beta-Darabinofuranosylcytosine-mediated differentiation and apoptosis. Cell Growth Differ. 7:1996;1617-1623.